Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
- Written by PR Newswire
![]() |
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout
SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion of an End-of-Phase 2 meeting with US FDA for its...
Read more: Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program















